

Tiago Torres

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7374088/publications.pdf>

Version: 2024-02-01

116
papers

2,438
citations

185998

28
h-index

253896

43
g-index

120
all docs

120
docs citations

120
times ranked

3022
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry—based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 60-71.	1.5	136
2	Update on Atopic Dermatitis. <i>Acta Medica Portuguesa</i> , 2019, 32, 606-613.	0.2	126
3	Toxicity screening of Diclofenac, Propranolol, Sertraline and Simvastatin using Danio rerio and Paracentrotus lividus embryo bioassays. <i>Ecotoxicology and Environmental Safety</i> , 2015, 114, 67-74.	2.9	103
4	JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. <i>Drugs</i> , 2020, 80, 341-352.	4.9	101
5	Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 783-798.	3.3	73
6	Palmoplantar Psoriasis and Palmoplantar Pustulosis: Current Treatment and Future Prospects. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 349-358.	3.3	71
7	Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 567-579.	3.3	65
8	Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 23-32.	3.3	64
9	JAK/STAT inhibitors for the treatment of atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2020, 31, 33-40.	1.1	64
10	Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 307-311.	3.3	60
11	Nail psoriasis as a predictor of the development of psoriatic arthritis. <i>Actas Dermo-sifiligráficas</i> , 2015, 106, 452-457.	0.2	59
12	The Protective Role of HLA-DRB1 $$\leq 13$ in Autoimmune Diseases. Journal of Immunology Research, 2015, 2015, 1-6.$	0.9	57
13	Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, e14-e15.	0.6	54
14	Screening the Toxicity of Selected Personal Care Products Using Embryo Bioassays: 4-MBC, Propylparaben and Triclocarban. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1762.	1.8	48
15	Risk of tuberculosis reactivation with interleukin (IL) 17 and IL23 inhibitors in psoriasis — time for a paradigm change. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 824-834.	1.3	48
16	More than skin deep: the systemic nature of atopic dermatitis. <i>European Journal of Dermatology</i> , 2019, 29, 250-258.	0.3	48
17	A revolutionary therapeutic approach for psoriasis: bispecific biological agents. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 751-754.	1.9	46
18	Treatment goals for psoriasis: Should PASI 90 become the standard of care?. <i>Actas Dermo-sifiligráficas</i> , 2015, 106, 155-157.	0.2	43

#	ARTICLE	IF	CITATIONS
19	Methyl-triclosan and triclosan impact embryonic development of <i>Danio rerio</i> and <i>Paracentrotus lividus</i> . <i>Ecotoxicology</i> , 2017, 26, 482-489.	1.1	42
20	Levels of Physical Activity in Patients with Severe Psoriasis: A Cross-Sectional Questionnaire Study. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 129-135.	3.3	40
21	No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1653-1659.	1.0	39
22	Pediatric Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 797-811.	3.3	39
23	Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 273-275.	0.6	39
24	Small Molecules in the Treatment of Psoriasis. <i>Drug Development Research</i> , 2015, 76, 215-227.	1.4	38
25	Epicardial adipose tissue and coronary artery calcification in psoriasis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 270-277.	1.3	38
26	Guselkumab for the treatment of psoriasis – evidence to date. <i>Drugs in Context</i> , 2019, 8, 1-11.	1.0	35
27	Cardiovascular comorbidities in childhood psoriasis. <i>European Journal of Dermatology</i> , 2014, 24, 229-235.	0.3	30
28	Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis. <i>BioDrugs</i> , 2019, 33, 391-399.	2.2	30
29	<p>Diagnosis, Screening and Treatment of Patients with Palmoplantar Pustulosis (PPP): A Review of Current Practices and Recommendations</p>. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2020, Volume 13, 561-578.	0.8	28
30	Guselkumab for the Treatment of Psoriasis. <i>BioDrugs</i> , 2018, 32, 119-128.	2.2	27
31	Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey*. <i>British Journal of Dermatology</i> , 2021, 185, 80-90.	1.4	26
32	Maintenance treatment of psoriasis with cyclosporine A: Comparison between continuous and weekend therapy. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 341-342.	0.6	23
33	ramingham risk score underestimates cardiovascular disease risk in severe psoriatic patients: Implications in cardiovascular risk factors management and primary prevention of cardiovascular disease. <i>Journal of Dermatology</i> , 2013, 40, 923-926.	0.6	23
34	Tofacitinib: A New Oral Therapy for Psoriasis. <i>Clinical Drug Investigation</i> , 2018, 38, 101-112.	1.1	23
35	Erectile dysfunction in psoriasis patients. <i>European Journal of Dermatology</i> , 2014, 24, 482-486.	0.3	22
36	Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab. <i>Drugs</i> , 2017, 77, 1493-1503.	4.9	22

#	ARTICLE	IF	CITATIONS
37	New Topical Therapies for Psoriasis. American Journal of Clinical Dermatology, 2022, 23, 13-24.	3.3	21
38	Conjunctivitis in patients with atopic dermatitis treated with dupilumab. Drugs in Context, 2020, 9, 1-8.	1.0	20
39	Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib. Dermatology Practical and Conceptual, 2021, 11, e2021145.	0.5	20
40	Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors. European Journal of Dermatology, 2016, 26, 3-8.	0.3	19
41	Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e636-e640.	1.3	18
42	Bimekizumab for the Treatment of Psoriasis. Drugs, 2021, 81, 1751-1762.	4.9	18
43	Mechanical Properties of Topical Anti-Psoriatic Medicines: Implications for Patient Satisfaction with Treatment. AAPS PharmSciTech, 2019, 20, 36.	1.5	17
44	Patient preferences for attributes of topical anti-psoriatic medicines. Journal of Dermatological Treatment, 2019, 30, 659-663.	1.1	15
45	Tralokinumab for the Treatment of Atopic Dermatitis. American Journal of Clinical Dermatology, 2021, 22, 625-638.	3.3	15
46	Poroceratose superficial disseminada num doente com colangiocarcinoma: manifesta�o paraneopl�sica?. Anais Brasileiros De Dermatologia, 2010, 85, 229-231.	0.5	14
47	The role of antinuclear autoantibodies in patients with psoriasis treated with anti-tumor necrosis factor-alpha agents: A retrospective long-term study. Journal of the American Academy of Dermatology, 2012, 66, e180-e182.	0.6	14
48	Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis. Actas Dermo-sifiligr�ficas, 2017, 108, 305-314.	0.2	14
49	A Systematic Review With Network Meta-Analysis of the Available Biologic Therapies for Psoriatic Disease Domains. Frontiers in Medicine, 2020, 7, 618163.	1.2	14
50	Dupilumab for atopic dermatitis: evidence to date. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 696-713.	0.8	14
51	Methodologies for medication adherence evaluation: Focus on psoriasis topical treatment. Journal of Dermatological Science, 2016, 82, 63-68.	1.0	13
52	Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab. European Journal of Dermatology, 2017, 27, 528-530.	0.3	13
53	Psoriasis: The visible killer. Revista Portuguesa De Cardiologia, 2014, 33, 95-99.	0.2	12
54	Complement C3 as a marker of cardiometabolic risk in psoriasis. Archives of Dermatological Research, 2014, 306, 653-660.	1.1	12

#	ARTICLE	IF	CITATIONS
55	Selective IL-13 inhibitors for the treatment of atopic dermatitis. <i>Drugs in Context</i> , 2021, 10, 1-17.	1.0	12
56	Hydrogels: A Promising Vehicle for the Topical Management of Atopic Dermatitis. <i>Advanced Therapeutics</i> , 2021, 4, 2100028.	1.6	12
57	Widespread comedones as the sole clinical manifestation of follicular mycosis fungoides. <i>European Journal of Dermatology</i> , 2010, 20, 534-535.	0.3	12
58	Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2911-2918.	1.1	12
59	IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk?. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 107-112.	3.3	11
60	Dupilumab para el tratamiento de la dermatitis atópica. <i>Actas Dermo-sifiligráficas</i> , 2018, 109, 230-240.	0.2	11
61	An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1045-1053.	2.0	11
62	Targeted Therapy for Pediatric Psoriasis. <i>Paediatric Drugs</i> , 2021, 23, 203-212.	1.3	11
63	Baricitinib for the treatment of atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2404-2413.	1.1	11
64	Does the Vehicle Matter? Real-World Evidence on Adherence to Topical Treatment in Psoriasis. <i>Pharmaceutics</i> , 2021, 13, 1539.	2.0	11
65	Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. <i>British Journal of Dermatology</i> , 2022, 187, 254-256.	1.4	11
66	Superficial cutaneous leiomyosarcoma of the face: Report of three cases. <i>Journal of Dermatology</i> , 2011, 38, 373-376.	0.6	10
67	Psoriasis strikes back! Epicardial adipose tissue: Another contributor to the higher cardiovascular risk in psoriasis. <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 613-616.	0.2	10
68	Lack of association between leptin, leptin receptor, adiponectin gene polymorphisms and epicardial adipose tissue, abdominal visceral fat volume and atherosclerotic burden in psoriasis patients. <i>Archives of Physiology and Biochemistry</i> , 2015, 121, 103-108.	1.0	9
69	Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date. <i>Psoriasis: Targets and Therapy</i> , 2018, Volume 8, 83-92.	1.2	9
70	Serum Levels of miR-146a in Patients with Psoriasis. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 475-485.	1.6	7
71	Bimekizumab: the new drug in the biologics armamentarium for psoriasis. <i>Drugs in Context</i> , 2021, 10, 1-4.	1.0	7
72	Epigenetic biomarkers as tools for chemical hazard assessment: Gene expression profiling using the model <i>Danio rerio</i> . <i>Science of the Total Environment</i> , 2021, 773, 144830.	3.9	7

#	ARTICLE	IF	CITATIONS
73	Tratamento de hidradenite supurativa com infliximab. Anais Brasileiros De Dermatologia, 2010, 85, 576-576.	0.5	7
74	Psoriasis, biologic therapy, and the pandemic of the 21st century. Drugs in Context, 2020, 9, 1-4.	1.0	7
75	Dupilumab for atopic dermatitis: a real-world Portuguese multicenter retrospective study. Journal of Dermatological Treatment, 2022, , 1-6.	1.1	7
76	Psoriasis: The visible killer. Revista Portuguesa De Cardiologia (English Edition), 2014, 33, 95-99.	0.2	6
77	Psoriasis strikes back! Epicardial adipose tissue: Another contributor to the higher cardiovascular risk in psoriasis. Revista Portuguesa De Cardiologia (English Edition), 2015, 34, 613-616.	0.2	6
78	Portuguese Position Paper on the Use of Biosimilars in Psoriasis. Acta Medica Portuguesa, 2016, 29, 574-577.	0.2	6
79	Biosimilars for Psoriasis – Experience from Europe. Current Dermatology Reports, 2019, 8, 26-34.	1.1	6
80	Etanercept-induced asthma in a psoriatic patient resolving with transition to ustekinumab. European Journal of Dermatology, 2012, 22, 696-697.	0.3	6
81	Tender tumor of the scalp: clinicopathologic challenge. International Journal of Dermatology, 2010, 49, 605-607.	0.5	5
82	Remission of psoriasis after autologous stem cell transplantation - until when?. European Journal of Dermatology, 2017, 27, 74-75.	0.3	5
83	The Changing Landscape of Atopic Dermatitis - Focusing on JAK Inhibitors. European Annals of Allergy and Clinical Immunology, 2020, 52, 45.	0.4	5
84	Paecilomyces lilacinus in transplant patients: an emerging infection. European Journal of Dermatology, 2010, 20, 643-4.	0.3	5
85	Treatment of palmoplantar pustulosis with ustekinumab – the importance of interfering with the IL23/Th17 pathway. European Journal of Dermatology, 2013, 23, 916-917.	0.3	4
86	Biologic therapy for psoriasis - still searching for the best target. Anais Brasileiros De Dermatologia, 2014, 89, 365-367.	0.5	4
87	Genetic Markers for Cardiovascular Disease in Psoriasis: The Missing Piece. Molecular Diagnosis and Therapy, 2014, 18, 93-95.	1.6	4
88	Influence of interleukin-6 gene polymorphisms in epicardial adipose tissue and coronary artery calcification in patients with psoriasis. British Journal of Dermatology, 2015, 172, 534-536.	1.4	4
89	Does treatment of metabolic syndrome components improve psoriasis? Report of three cases.. European Journal of Dermatology, 2012, 22, 270-272.	0.3	4
90	Portuguese recommendations for the treatment of psoriasis with biologic therapy. European Journal of Dermatology, 2020, 30, 645-654.	0.3	4

#	ARTICLE	IF	CITATIONS
91	Selective IL-23 Inhibitors: The New Kids on the Block in the Treatment of Psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2018, 109, 674-676.	0.2	3
92	Dermatologists'™ attitude towards psoriasis treatment during the COVID-19 pandemic. <i>Drugs in Context</i> , 2021, 10, 1-9.	1.0	3
93	Granuloma annulare of the penis " subcutaneous presentation. <i>European Journal of Dermatology</i> , 2011, 21, 448-449.	0.3	3
94	Sacroiliitis in a psoriasis patient after switching from etanercept to ustekinumab. <i>European Journal of Dermatology</i> , 2013, 23, 897-898.	0.3	3
95	Safety of secukinumab in psoriasis patients with latent tuberculosis infection. <i>European Journal of Dermatology</i> , 2020, 30, 740-741.	0.3	3
96	Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis Council. <i>JAAD International</i> , 2020, 1, 224-230.	1.1	3
97	A case of erythrokeratoderma variabilis with connexin 31 gene mutation (Cx31F137L). <i>International Journal of Dermatology</i> , 2012, 51, 494-496.	0.5	2
98	Multiple myeloma in a patient under ustekinumab " are they related?. <i>European Journal of Dermatology</i> , 2013, 23, 567-568.	0.3	2
99	Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 305-314.	0.2	2
100	Nail psoriasis as a predictor of the development of psoriatic arthritis. <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 452-457.	0.2	1
101	Awareness and screening attitudes of Portuguese dermatologists on cardiovascular risk factors in psoriatic patients. <i>European Journal of Dermatology</i> , 2017, 27, 443-445.	0.3	1
102	Risk of hepatitis B virus reactivation in patients treated with anti-TNF± agents for immune-mediated inflammatory diseases. <i>Actas Dermo-sifiliográficas</i> , 2018, 109, 285-287.	0.2	1
103	Inhibidores selectivos de la IL-23: los recién llegados al tratamiento de la psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2018, 109, 674-676.	0.2	1
104	A case of psoriasis and systemic lupus erythematosus successfully treated with ustekinumab. <i>European Journal of Dermatology</i> , 2021, 31, 429-431.	0.3	1
105	Patterns of dosage regimen instructions regarding topical medicines: how is the information perceived by patients?. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2325-2330.	1.1	1
106	Isolated tongue lesions as the sole presentation of secondary syphilis. <i>European Journal of Dermatology</i> , 2010, 20, 240-241.	0.3	1
107	Oral therapies for psoriasis and psoriatic arthritis: current knowledge and future perspectives. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 384-385.	0.8	1
108	Authors'™ reply to Borg and Thoning: "Comment on: Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study". <i>American Journal of Clinical Dermatology</i> , 2021, 22, 903-904.	3.3	1

#	ARTICLE	IF	CITATIONS
109	Influence of psoriasis lesions' location and severity on psychosocial disability and psychopathology. Observational study and psychometric validation of the SAPASI Portuguese version. <i>Journal of Psychosomatic Research</i> , 2022, 154, 110714.	1.2	1
110	Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients. <i>Drugs in Context</i> , 2021, 10, 1-12.	1.0	1
111	Residents'™ corner November 2011. Residents'™ editorial choice. <i>European Journal of Dermatology</i> , 2011, 21, 1029-1029.	0.3	0
112	Importance of educational sessions on cardiometabolic comorbidities. Awareness among psoriasis patients. <i>Actas Dermo-sifiligráficas</i> , 2016, 107, 539-541.	0.2	0
113	Pruritic erythematous plaque in the skin folds. <i>Australian Journal of General Practice</i> , 2021, 50, 294-295.	0.3	0
114	Residents'™ corner September 2011. Residents'™ editorial choice. <i>European Journal of Dermatology</i> , 2011, 21, 826-827.	0.3	0
115	Residents'™ corner September 2011. sQUIZ your knowledge!. <i>European Journal of Dermatology</i> , 2011, 21, 827-828.	0.3	0
116	Photo Rounds: Rapid-onset rash in child. <i>Journal of Family Practice</i> , 2018, 67, E1-E2.	0.2	0